bill, thannks for the distinction.. i love htis board and its funamental and technical analysis of prln..
the more i learn, the better i invest.
keep discussing what they make and their progess.. i am luckie if i take an aspirin correctly.. of course its bayer..
as to the comment by richard.. he is half right and half not right.. i think as he does, that the conference will bounce the stock. but, it will bounce because of the exposure to the world and because i think the good doctor will have up dates to present at that time. i was told he would present , as much as is "proper" at the conference ..to me that means lots of data from now til novemeber.
i think we are getting mixed up some times as we have two big drugs in testing..27 and 355..they work in different areas and each has multiple usage..
example, the 27, i thjnk it is, smooths the lining of the blood vesels after heart surgery so that they do not shrink back to constrictive size.
then, it the prostrate area..big plus here.
also, the doages of all their tests will be at diffent amounts as they are finding the point of greatest value effect.
my biggest point today is.. we know they have something, only we are not sure of what and its exact strength.. will cliniucal one tell us? or, do we need two and three to know we are on the road?
i know they are planning that consumer over the counter products for beginning of year.. thats what we need, some actual sales and usage ..
anyway, that november conference is big in my mind as it affects the stock.. |
